# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
EF Hutton analyst Jason Kolbert maintains Can Fite Biofarma (AMEX:CANF) with a Buy and maintains $10 price target.
Financial ResultsRevenues for the six months ended June 30, 2024 were $0.32 million compared to revenues of $0.39 million for t...
EF Hutton analyst Jason Kolbert initiates coverage on Can Fite Biofarma (AMEX:CANF) with a Buy rating and announces Price Ta...
Can-Fite plans to start shortly a Phase IIa clinical study that will be a multicenter open-label trial in patients with advance...
This Drug Candidate Is Currently Used In A Pivotal Phase 3 Study For Patients With Advanced Liver Cancer And A Phase 2b Study F...
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule dr...